ArticleJournal of hepatocellular carcinoma2025
The Prognostic Value of Lymphocyte-to-Monocyte Ratio for Long-Term Survival After TACE in Intermediate-to-Advanced Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Hepatic Fibrosis: Unpacking What a High FIB-4 Index Means in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the predictive value of the preoperative lymphocyte-to-monocyte ratio (LMR) for long-term survival in patients with intermediate-to-advanced hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE), providing a reference for precise clinical decision-making. Patients and Methods: A retrospective analysis was conducted on clinical data from 313 patients with intermediate-to-advanced HCC treated with TACE at Sichuan Provincial People's Hospital between February 2016 and September 2021. Cox regression analysis was used to identify independent risk factors affecting overall survival (OS). The optimal cut-off value for LMR was determined using receiver operating characteristic (ROC) curve analysis. Survival curves were generated using the Kaplan-Meier method, and differences between groups were compared using the Log rank test. Results: Univariate and multivariate regression analyses revealed that LMR (P=0.033), alpha-fetoprotein (AFP, P=0.007), tumor number (P=0.044), BCLC stage (P=0.013), systemic immune-inflammation index (SII, P=0.044), and fibrosis-4 index (FIB-4, P=0.040) were independent risk factors for OS. Kaplan-Meier survival analysis further demonstrated that, in addition to LMR, patients with AFP > 642.08 ng/mL, cholinesterase ≤ 4.55 kU/L, SII > 250.91, neutrophil-to-lymphocyte ratio (NLR) > 2.85, and FIB-4 > 4.51 also exhibited significantly lower survival rates (all P < 0.05). The optimal cut-off value for LMR was 2.71 (AUC=0.62). Patients with LMR ≤ 2.71 had a significantly lower 3-year survival rate (23.8%) compared to those with LMR > 2.71 (54.2%; log-rank χ² = 21.2, P<0.001). Conclusion: This study confirms that pre-treatment LMR is an independent predictor of overall survival following TACE in a cohort predominantly composed of patients with intermediate-to-advanced HCC classified as BCLC stage C. LMR may serve as a valuable complement to traditional prognostic models, providing incremental value for prognostic assessment in this specific patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.